Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract A038: The feasibility of inducing effective systemic immune responses to human metastatic melanoma with intralesional secreted cytokines

Fred T. Valentine, Frederick M. Golomb, Matthew Haris and Daniel F. Roses
Fred T. Valentine
NYU School of Medicine, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederick M. Golomb
NYU School of Medicine, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Haris
NYU School of Medicine, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel F. Roses
NYU School of Medicine, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A038 Published January 2016
  • Article
  • Info & Metrics
Loading
Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY

Abstract

The induction of new additional immune responses to potential neoantigens on metastatic melanoma resulting in dense lymphocytic infiltrates might cause regression of metastases and could enhance the effects of anti-check point therapies.

The blocking of CTLA-4 or PD-1/PD-L1, which normally constrain immune responses, results in significant prolongation of life and up to 7% complete responses (CRs) of metastatic melanoma when used individually. Insufficient nascent anti-melanoma immunity may account for the relatively low frequency of CRs. Also the lack of specificity in the dis-inhibition of immune responses can cause adverse reactions. We investigated a different strategy: inducing new specific immune responses to metastatic melanoma with mixed secreted cytokines.

The development of immune responses is regulated by multiple cytokines/chemokines (CKs) acting in concert. To mimic this secretory environment, in a non-randomized prospective study, 88 patients with multiple palpable cutaneous/subcutaneous metastases (stages IIIC and IV-M1a) received weekly injections of autologous secreted CKs into some metastatic nodules while other metastases were never injected. CKs were prepared ex-vivo by stimulating PBMCs with recall microbial antigens to which the patients were sensitive as assessed by PBMC proliferative responses. The secreted mixtures contained individual cytokines at picogram to nanogram concentrations. New immune responses were identified by the development of dense lymphocytic infiltrates in never-injected metastases, consisting of CD8 and smaller numbers of CD4 T cells. This study was conducted before the availability of current therapies.

After multiple injections into some metastatic nodules, never-injected metastases developed dense tumor-infiltrating lymphocytes (TILs) and often regressed completely. CD8 TILs from metastases directly killed fresh autologous melanoma cells ex-vivo in an MHC-restricted manner without in- vitro boosting. Although both never-injected and injected metastases often regressed completely, in some patients new metastases appeared even while never- injected nodules were regressing. The new metastases often regressed with or without injections. In 40% of subjects all never-injected and injected metastases regressed completely for > 2 months. 20% remained free of disease for 5 to 28 years (median 60 months, range 2 to 334 months). Median overall survival of patients, progressing and regressing, was 28.5 months (4-348 months), with 55% of patients surviving 2 years, and 30% 5 years. Durable disease-free survival also occurred in recipients of intracutaneous CKs mixed with irradiated autologous melanoma cells. No adverse events occurred.

We conclude that intralesional secreted, mixed CKs can induce new systemic and effective cellular immune responses to metastatic melanoma. Mixtures of secreted cytokine/chemokines (CKs) may be more effective in inducing the development of immune responses than individual CKs. These immune responses were associated with a surprisingly high frequency (40%) of complete regressions and prolonged disease-free periods of 1 to 28 years. These new anti-melanoma cellular immune responses also might enhance the frequency of clinical responses to subsequent anti-check point therapies.

Citation Format: Fred T. Valentine, Frederick M. Golomb, Matthew Haris, Daniel F. Roses. The feasibility of inducing effective systemic immune responses to human metastatic melanoma with intralesional secreted cytokines. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A038.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 4 (1 Supplement)
January 2016
Volume 4, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A038: The feasibility of inducing effective systemic immune responses to human metastatic melanoma with intralesional secreted cytokines
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A038: The feasibility of inducing effective systemic immune responses to human metastatic melanoma with intralesional secreted cytokines
Fred T. Valentine, Frederick M. Golomb, Matthew Haris and Daniel F. Roses
Cancer Immunol Res January 1 2016 (4) (1 Supplement) A038; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A038

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A038: The feasibility of inducing effective systemic immune responses to human metastatic melanoma with intralesional secreted cytokines
Fred T. Valentine, Frederick M. Golomb, Matthew Haris and Daniel F. Roses
Cancer Immunol Res January 1 2016 (4) (1 Supplement) A038; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A038
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement